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INTRODUCTION
    
      Resistance to antimicrobials among bacterial pathogens is a rapidly emerging global 
problem [1]. Antimicrobial resistance (AMR) is not just a problem in the hospital setting 
but has already spread to the community. Multidrug resistance has become a reality in the 
management of many important infections. This limits the choice of therapy, increases 
mortality, morbidity and the cost. Although the exact magnitude of economic burden and 
social issues related to AMR are not known, especially from developing countries, it is 
also likely to be significant. Hence it becomes important to understand the issues related 
to emergence and spread of AMR in bacteria. 
            The evolution of resistance has two key steps i.e., emergence and dissemination. 
Emergence results from mutations in housekeeping structural or regulatory genes or from 
acquiring new genetic information. Dissemination can occur at the level of the bacteria 
(Clonal spread) or at the genetic level (plasmids and transposons). In order to control the 
increasing prevalence of AMR it is probably easier for us to interfere with dissemination 
than with emergence. Understanding the mechanisms of AMR will help us to elucidate 
the most likely method of emergence and dissemination and therefore develop methods 
for preventing it [2].   
Urinary tract infections (UTI) are considered to be the third most common cause 
of hospital visits in India [3]. Many different microorganisms can infect the urinary tract, 
but by far the most common agents are gram-negative bacilli of which Escherichia coli is 
the commonest, accounting for 85% of community acquired UTI and 50% of hospital 
acquired UTI [4-6]. For UTI, drugs like amoxicillin and cotrimoxazole used to be the 
mainstay of oral therapy. These agents are no longer recommended as reliable because 
over 50% of isolates from community acquired UTI are now resistant to these agents [7]. 
Resistance to oral cephalosporins is also increasing. This would mean that there might be 
many clinical and microbiological failures, if these drugs are used [8]. 
    
Therefore fluoroquinolones became the most widely used antibiotics for the 
treatment of UTI. The expanded spectrum quinolones such as norfloxacin and 
ciprofloxacin were highly active against gram-negative bacilli and eradicated bacteruria 
in more than 90% cases of UTI [9]. However, this scenario is also changing with rapid 
development of resistance among gram-negative bacilli to these drugs [10].  
Multiple studies have demonstrated increasing resistance to fluoroquinolones. A 
study of E. coli isolates from women in America with uncomplicated cystitis has shown a 
3.5 fold increase in ciprofloxacin resistance from 1995 – 2001. According to a Dutch 
surveillance study E. coli resistance to norfloxacin has increased from 1.3% in 1989 to 
5.8% in 1998. In South Korea, UTI caused by quinolone resistant E.coli has increased 
from 14.4% in 1996 to 21.3% in 2000 [11]. According to our data, 20-22% of E.coli 
isolated from antenatal women with UTI are resistant to fluoroquinolones. The resistance 
rates are as high as 70-90%in hospital strains causing UTI [5].  
 Therefore it was considered important to understand the mechanisms of 
fluoroquinolone resistance and its association with resistance to other antimicrobials in 
current use. A study was therefore undertaken for this purpose and also to understand the 
clonal spread of fluoroquinolone resistant (FQR) E.coli in our hospital and in the 
community.   
  
 
 
 
 
 
 
 
 
 
 
 
    
                                        
 
 
 
 
 
 
                                     
                                           AIMS AND  
       OBJECTIVES
    
2.1 Aim: 
 To describe possible mechanisms for fluoroquinolone résistance (FQR), to document 
the susceptibility patterns of FQR E.coli causing Urinary tract infections (UTI) and to 
ascertain whether these organisms belong to a single clone.  
 
2.2 Objectives: 
 
1) To determine the prevalence of efflux pump mediated FQR among E.coli causing UTI. 
2) To determine the prevalence of high-level resistance to nalidixic acid among FQR 
E.coli as a phenotypic marker of gyr A mutations.  
3) To type FQR E.coli using Random Amplified Polymorphic DNA pattern. 
4) To determine the prevalence of resistance to other antimicrobials like aminoglycosides 
     and cephalosporins among the FQR E.coli. 
5) To determine the prevalence of extended spectrum beta lactamase (ESBL) production  
     among FQR E.coli. 
 
 
 
 
 
 
  
 
 
 
 
    
                                
 
 
 
 
                                                       
 
                                                       REVIEW OF  
                   LITERATURE 
    
   Quinolones have been the center of considerable scientific and clinical interest since 
their discovery in the early 1960s. This is because they potentially offer many of the 
attributes of an ideal antibiotic, combining high potency, a broad spectrum of activity, 
good bioavailability, high serum levels, wide distribution, oral and intravenous 
formulations and a potentially low incidence of side effects. They target the bacterial 
DNA replication and maintenance [12]. 
3.1 History:  
The first member of the quinolone class of anti microbial agents is nalidixic acid 
which is a 1,8 naphthyridine structure [8]. It was identified by George Lesher and his 
associates in 1962 among the by products of chloroquine synthesis [13]. In 1975 Smith et 
al demonstrated that nalidixic acid inhibits a critical enzyme for bacterial multiplication. 
Subsequently Gellert et al purified the enzyme and named it as DNA gyrase 
(topoisomerase II) [14]. The therapeutic utility of nalidixic acid was limited to the 
treatment of gram-negative infections of the urinary tract [13]. 
              Newer quinolones like pipemidic acid, oxolinic acid and cinoxacin were 
introduced in the late 1970s [13]. These were somewhat more potent but the real 
breakthrough was achieved in the early 1980s by the addition of fluorine atom at the C6 
position and piperazine substituents at C7 position of the basic quinolone structure. This 
was the beginning of the era of “fluoroquinolones”[15]. They had high potency, expanded 
spectrum, slow development of resistance, better tissue penetration and good tolerability. 
These agents were not only potent against gram-negative bacteria but also had limited 
activity against Gram positives and anaerobes [11]. In the 1990s further alterations of the 
quinolones resulted in the discovery of novel compounds that had better activity against 
gram-positive aerobic bacteria and anaerobes with some loss of gram-negative coverage 
[11, 14].  Newer compounds such as trovafloxacin have also shown promising activity 
    
against anaerobes [11, 16]. Recently, non-fluorinated quinolones have been developed 
further opening novel avenues in the development of quinolones [8]. 
3.2 Structure: 
 All quinolone derivatives have a dual ring structure (fig: 3.1a & b) with nitrogen 
at position 1, a carboxyl group attached to the carbon at position 3 of the first ring and a 
carbonyl group at position 4 [8].  
 Fig: 3.1(a) – Nalidixic acid 
 
Fig: 3.1(b) – Norfloxacin  
         
      
Nalidixic acid is a 1,8 naphthyridine with 1 ethyl and 7 methyl substituents. In 
case of fluoroquinolones fluorine is added at position 6 to improve the potency. Potency 
against gram-negative bacteria is further enhanced by the addition of piperazenyl 
(norfloxacin, ciprofloxacin), methylpiperazenyl (pefloxacin, ofloxacin, lomefloxacin) and 
dimethyl piperazenyl groups (sparfloxacin). Pyrrolidinyl substitution improves 
bactericidal activity against gram-positive organisms [8]. 
 
 
    
3.3 Classification: 
     This class of antimicrobials has undergone several decades of structural 
refinements (table 3.1). They can be categorized as follows [16]. 
I - Nalidixic acid and two variants - oxolinic acid and cinoxacin. 
Their use is limited only to gram-negative infections.  
II - First group of fluoroquinolones. They are further divided in to IIa and IIb. 
            IIa: Ciprofloxacin, norfloxacin, ofloxacin, levofloxacin     
 These are effective against gram-negative infections. Their main disadvantage is, 
            limited activity against Gram-positive pathogens.                         
            IIb: Temofloxacin and grepafloxacin. 
            Consists of compounds, with a broader spectrum of activity encompassing the  
            Gram-positive organisms. They have a longer half-life, which permits for a once 
            daily dosing.                 
III - They are further divided in to IIIa and IIIb. 
            IIIa: Gatifloxacin, moxifloxacin, trovafloxacin 
 This group has a broader antimicrobial spectrum particularly against  
Streptococcus pneumoniae, Mycoplasma spp and Chlamydia spp at the loss of     
some gram-negative coverage. Trovafloxacin has activity against anaerobes also. 
            IIIb: Gemifloxacin is currently the only generation IIIb quinolone in phase III 
development. This has good activity against ciprofloxacin resistant and 
penicillin resistant strains of S.pneumoniae. 
IV - Desfluoroquinolones: 
 These are novel compounds that lack the fluorine atom at the C6 position of the 
quinolone structure. The mechanism of action is similar to other fluoroquinolones with 
the primary target being DNA gyrase. They have a broad spectrum of antibacterial 
    
activity, which includes anaerobes, gram-positive bacteria and quinolone resistant 
pathogens. These agents are claimed to have lesser incidence of joint toxicity [17]. 
 
Table 3.1: Antibacterial spectrum and adverse effects of some quinolones [16]: 
S.NO. GENERATION NAME OF THE DRUG           ANTIMICROBIAL SPECTRUM ADVERSE EFFECTS  
  1        I Nalidixic acid* Active against common enterobacteriaceae GI upset, rashes, 
CNS effects 
  2       II Ciprofloxacin* 
Norfloxacin* 
Ofloxacin* 
Sparfloxacin 
Levofloxacin* 
Enhanced activity, mainly against Gram-
negative pathogens; limited potency 
against Gram-positive pathogens and 
methicillin-resistant Staphylococcus 
aureus, ciprofloxacin most active against 
P. aeruginosa 
Cartilage damage 
in children, 
gastrointestinal, 
skin rashes and 
allergic reactions.  
  3 III Trovafloxacin 
Gatifloxacin* 
Moxifloxacin 
 
Enhanced activity against Gram-positive 
pathogens; retained activity against 
ciprofloxacin-resistant pneumococci; 
highly active against atypical respiratory 
tract infection pathogens; reduced activity 
versus Gram-negative pathogens 
 CNS effects, 
hepatic damage, 
phototoxicity and 
allergic reactions  
 
*  Agents currently in clinical use. 
 
 
 
 
 
 
 
    
3.4 Mechanism of action: 
  Quinolones rapidly inhibit DNA synthesis bringing about cell death. They inhibit 
enzymatic activities of the topoisomerase class of enzymes. The topoisomerases consist 
of four enzymes namely topoisomerase – I, topoisomerase – II or DNA gyrase, 
topoisomerase – III, and topoisomerase – IV. The main targets of fluoroquinolones are 
DNA gyrase and topoisomerase – IV encoded by gyrA, gyr B and parC, parE genes 
respectively [18]. 
 DNA gyrase: 
 It is a bacterial enzyme composed of two A and two B subunits, which catalyses 
the introduction of negative supercoils into the linear DNA double helix. This process is 
initiated by, binding of the tetrameric enzyme to the double stranded DNA helix leading 
to cleavage of the DNA strands at staggered sites. This is followed by the passage of 
another segment of the DNA through the break and resealing.  Supercoiling is essential 
for the well being of the bacteria, as it enables them to accommodate their chromosome 
(1300μ long) with in their cell envelope (2μ x 1μ) and also affects the initiation of DNA 
replication and transcription of many genes [19, 20]. 
Topoisomerase IV: 
 It is structurally related to DNA gyrase. It separates the daughter DNA after 
replication [21].  
3.4.1 Inhibition by quinolones: 
Quinolones inhibit the action of DNA gyrase by binding to the enzyme-DNA 
complex after strand breakage and before the resealing of DNA .The drug-DNA-enzyme 
complex generates a permanent DNA break that the cell is unable to repair. This leads to 
irreversible damage to the DNA followed by cell death [8].  
    
For many gram-negative bacteria DNA gyrase is the primary quinolone target. On 
the other hand topoisomerase IV is the primary target for many gram-positive bacteria. 
Other enzymes serve as secondary targets in both cases [18, 19]. 
In addition to the initial interaction of fluoroquinolones with the DNA 
topoisomerase complex bacterial killing may need the synthesis of certain new gene 
products. This explains the fact that certain drugs, which inhibit RNA and protein 
synthesis, reduce the bactericidal activity of quinolones but don’t affect their ability to 
inhibit bacterial DNA synthesis. A similar situation may arise at high concentrations of 
quinolones where there is secondary inhibition of protein synthesis and reduced bacterial 
killing. The nature of the gene product that contributes to the killing is yet to be defined 
[8]. 
3.5 Pharmacokinetics: 
3.5.1 Absorption: 
 Quinolones are well absorbed from the upper GIT with the bioavailability 
exceeding 50 % for all compounds. Peak concentrations are reached in the serum usually 
within 1 to 3 hours of administering dose. Concentrations in prostate, stool, bile, lungs, 
neutrophils and macrophages usually exceed serum concentration. Concentrations in 
urine and kidney are high for quinolones with major renal route of elimination. 
Concentrations of quinolones in saliva, prostatic fluid, bone and CSF are lower than 
concentration in serum. 
Aluminium, magnesium and calcium containing antacids lower the oral 
bioavailability of quinolones due to the formation of cation-quinolone complex, which is 
poorly absorbed. Ferrous sulphate, multi-vitamins, Zinc and buffered formulations of 
dideoxyionose also reduce quinolone absorption. Ranitidine reduces enoxacin absorption 
by 60% and omeprazole reduces trovafloxacin absorption by 17%. Intravenous 
    
formulations of ciprofloxacin and pefloxacin get precipitated when they are infused with 
aminophylline, flucloxacillin or amoxicillin with or without clavulanic acid [8, 12].  
3.5.2 Elimination:  
 The terminal half lives of elimination from the serum range from 3 hours for 
norfloxacin and ciprofloxacin to 20 hours for sparfloxacin. Principal routes of elimination 
differ for different quinolones. They are renal and non-renal as shown in table 3.2. 
Table 3.2: Routes of elimination of fluoroquinolones: 
Renal Non renal (Hepatobiliary) 
Ofloxacin 
Lomefloxacin 
Ciprofloxacin 
Pefloxacin 
Sparfloxacin 
Trovafloxacin 
  
Transintestinal secretion has been identified for the intravenous administration of 
ciprofloxacin and accounted for about 10 to 15 % of drug excretion [8, 12]. 
3.6 Resistance to Antimicrobials: 
3.6.1 General information: 
Antimicrobial resistance (AMR) is a natural biological response of microbes to 
the selective pressure of an antimicrobial drug. Drug resistance can be described as a state 
of insensitivity or of decreased susceptibility of microorganisms to drugs that ordinarily 
cause growth inhibition or cell death [22]. 
 The discovery of an antimicrobial agent by Paul Ehrlich was one of the most 
remarkable discoveries that changed the face of medical practice. The increased global 
flow of antimicrobials brought with it the threat of increased AMR [22]. Resistance can 
result from modification or functional by passing of an antibacterial’s target or can be 
contingent on impermeability, efflux or enzymatic inactivation. All these could be either 
inherent or acquired [23]. Most bacteria have multiple modes of AMR to any drug  
    
and once resistance develops they can rapidly give rise to vast numbers of resistant 
progeny [23]. 
3.6.2 Types of resistance: 
1) Physiological resistance to antibiotics: 
Resistance can be physiological, meaning that resistance is only expressed during 
certain growth conditions. The most discussed type of physiological resistance is that 
seen in bacterial biofilms. Bacteria growing in the biofilms are difficult to eradicate with 
antibiotic treatment. The actual mechanism behind this physiological resistance is far 
from clear. Various reasons have been discussed. One reason is that the organisms are in 
a balanced state of growth and death. In the stationary phase and during biofilm mode of 
growth, persisters might occur in large numbers. Many antibiotics do not directly kill the 
microbe but trigger a program within the organism itself that leads to death. This mode of 
action may not be possible with metabolically inactive cells like persisters [24]. 
The location of the microbe during infection may in some instances prevent the 
drug from reaching appropriate concentrations where the microbe is growing. This could 
be another reason for physiological resistance. For example, E.coli expressing type I 
fimbriae may be internalized by uroepithelial cells during a bladder infection. It is 
therefore possible that recurrent UTI in women by E.coli, despite antibiotic treatment, 
could be the result of an outgrowth from a small number of intracellularly located 
organisms surviving the treatment [25]. 
2) Intrinsic antibiotic resistance: 
 It is the natural resistance possessed by bacteria to certain antibiotics and not 
associated with any additional genetic alteration. For example, Mycoplasma spp are 
always resistant to beta lactam antibiotics as they lack peptidoglycan as a cell wall 
component [24]. 
    
  Many enteric bacterial species including Pseudomonas aeruginosa exhibit a very 
low susceptibility to hydrophobic antibiotics like macrolides because they are unable to 
penetrate the outer membrane of these organisms. Their susceptibility to hydrophilic 
antibiotics is determined by the rate of permeation of the antibiotic through water filled 
protein channels (porins) in the outer membrane. In P. aeruginosa the low total surface 
area of the porins in the outer membrane confers high resistance to hydrophilic antibiotics 
also [26, 27]. 
3) Acquired antibiotic resistance: 
 Acquired antibiotic resistance occurs either by mutations or by horizontal gene 
transfer. For each class of antibiotics there are usually a number of mechanisms that can 
cause resistance. These mechanisms may also differ depending on the bacterial species 
and its genetic make-up [24]. 
The main mechanisms of resistance include:  
a) Decreased uptake and increased elimination of drug:   
Alterations in porins are usually associated with up regulated efflux and 
elimination of drugs. This is the type of resistance, seen in many carbapenem resistant 
P.aeruginosa [28].  
b) Trapping:  
 Trapping is an alternative mechanism for lowering the intracellular concentrations 
of antibiotics. Binding of the antibiotic to enzymes prevents the binding to target proteins 
even in the absence of drug destruction. This phenomenon has been observed in AMR to  
β-lactam antibiotics that are resistant to hydrolysis by β-lactamases. This mechanism has 
also been reported in aminoglycoside resistance and in low-level resistance to 
glycopeptides among Staphylococcus spp [29].  
 
    
c) Modification of the drug target:  
Mutations in the 16S rRNA, limits the tetracycline binding to its target site at the 
30S subunit of the ribosome in Helicobacter pylori thereby disrupting its ability to inhibit 
protein synthesis and cell growth [30].   
d) Introduction of new drug resistant targets: 
A penicillin binding protein (PBP) that has a low affinity to βlactam antibiotics 
mediates methicillin resistance in Staphylococcus aureus [31].  
e) Enzymatic hydrolysis of the antibiotic:  
β-lactamases produced by bacteria inactivate the βlactam antibiotics by splitting 
the amide bond of the β-lactam ring [30]. 
f) Modification of the antibiotic:  
Resistance to aminoglycosides is mediated by drug modifying enzymes like 
acetyltransferases (AAC), nucleotidyl transferases (ANT) and phosphotransferases (APH) 
[32]. 
g) Bypass of metabolic pathways:  
Sulfonamides exert their antibacterial action by disrupting bacterial folic acid 
synthesis from para amino benzoic acid (PABA) by a competitive inhibition of the 
enzyme dihydropteroate synthase. AMR to sulfonamides can result from the synthesis of 
a new dihydropteroate synthase that has poor affinity for sulfonamides [33, 34].   
3.7 Mechanism of Fluoroquinolone resistance: 
The two principal mechanisms by which bacteria acquire resistance to 
fluoroquinolones are 
(1) Alterations in the drug targets.  
(2) Decreased accumulation of the drug inside the bacteria due to impermeability of the 
      membrane and /or over expression of efflux pump systems [35]. 
 
    
 These mechanisms are due to mutations in the chromosomal genes encoding for the 
targets or those controlling the expression of outer membrane porin proteins and 
endogenous multidrug efflux pumps. Majority of studies on the mechanism of action and 
resistance to quinolones have been done on enterobacteriaceae especially E.coli [35]. 
3.7.1 Target alterations: 
a) Alterations in DNA gyrase: 
gyrA and gyr B genes encode the A and B subunits of the DNA gyrase respectively. 
Among resistant strains obtained from clinical isolates there is a significant 
preponderance of mutations in gyrA. However mutations in gyrA and gyrB are found in 
equal proportions among resistant E.coli strains obtained from other sources [35]. The 
point mutations responsible for quinolone resistance in E.coli result in changes within the 
region between the amino acids 67 and 106 of the GyrA protein. This region is known as 
the quinolone resistance-determining region (QRDR) and is located in the N- terminal 
region of the GyrA protein close to the tyrosine 122, which is the binding site of the 
cleaved DNA [35-37]. 
Mutations affecting codons 67,81, 82, 83, 84, 87 and 106 of gyrA have been 
observed to be responsible for quinolone resistance in E. coli. A part of these mutations 
can even occur in position 51, a region outside the QRDR, which would result in 
decreased susceptibility to quinolones. The most frequent mutation associated with 
quinolone resistance in clinical isolates of E.coli affects codon 83 of gyrA. The second 
most common mutation affects codon 87 [35]. 
Resistance levels are dependent on the site and number of mutations. Quinolone 
minimum inhibitory concentrations (MIC) are highest for mutants with mutations at 
codon 83 followed by those with mutations at codons 87,81,84,67 and 106 in decreasing 
order [36] . Resistance levels conferred by mutations at both sites (83 and 87) can be two 
    
to three folds higher than when only one position is mutated. Additional mutations in the 
parC gene further increase the level of resistance [38]. The level of resistance and there 
by the MIC is also determined by the specific amino acid substitution. For example, point 
mutations in the codon for serine 83 can induce substitution by leucine, tryptophan, 
proline or threonine. Serine 83 to leucine substitution is the commonest and confers the 
greatest reduction in susceptibility to quinolones [35, 36].  
 Quinolone resistance determining aminoacid substitutions have been described at 
positions 426 (Asp 426 to Asn) and 447 (lysine 447 to Glu) of the Gyr B protein of E.coli. 
Substitutions at position 426 confer resistance to all quinolones, whereas those at position 
447 result in an increased level of resistance to nalidixic acid, but greater susceptibility to 
fluorinated quinolones [35]. 
b) Alterations in Topoisomerase IV: 
 parC and parE genes encode the A and B subunits of the topoisomerase IV 
respectively. Though gyrA mutations play a major role in the development of 
fluoroquinolone resistance in E.coli, parC mutations are additionally associated with 
resistance. Resistance mutations in parC gene of E.coli most commonly occur at positions 
80 and 84 leading to substitution of serine 80 and glutamic acid 84 by hydrophobic and 
positively charged amino acids [35, 38]. Another substitution, glycine 78 to aspartate has 
also been described in quinolone resistant E.coli.Aminoacid substitutions in parE do not 
contribute to the development of quinolone resistance [35]. 
c) Sequential mutations: 
 Stepwise increase in AMR to fluoroquinolones is brought about by sequential 
mutations in the gyrA (or gyrB) and parC (or parE) genes. The first step mutation occurs 
in a gene for the more sensitive target enzyme  (gyrA in E.coli). For example, mutation at 
codon 83 of the gyrA normally leads to moderate level resistance to quinolones like 
    
nalidixic acid. Resistance is increased by the addition of one or two parC mutations. 
Three mutations (two gyrA and one parC) lead to high-level resistance and four mutations 
(two gyrA and two parC) are associated with very high levels of resistance and FQR [8, 
38].  
3.7.2 Decreased accumulation of the drug: 
Quinolone accumulation with in the bacterial cell can be reduced by two 
mechanisms: 
1. Increase in the bacterial cell wall impermeability  
2. Over expression of efflux pumps 
The two mechanisms operate synergistically and can be induced. 
 Transport of quinolones across the outer membrane is either through specific 
porins or by diffusion through the phospholipid bilayer. Thus alterations in the 
composition of porins or in the lipopolysaccharides can lead to alterations in the 
susceptibility to quinolones [35]. 
 The outer membrane of E.coli consists of three main porins namely ompA, ompC 
and ompF. Decreased expression of ompF is associated with reduced susceptibility to 
certain quinolones and also to other antibacterial agents such as βlactams, tetracyclines 
and chloramphenicol [35]. 
 Around 37 different putative efflux pump systems have been described in E.coli 
[39]. The most important fluoroquinolone efflux system is the AcrABTolC (encoded by 
the acrABtolC gene). This system is expressed in wild strains under normal laboratory 
growth conditions and contributes to intrinsic resistance. Another efflux system known as 
the AcrEF (encoded by the acrEF genes) is not expressed in wild type strains but has the 
same substrate specificity as that of the former. The most striking feature of the 
fluoroquinolone efflux systems is their broad substrate specificity encompassing a variety 
    
of structurally unrelated antimicrobial agents, including clinically relevant antibiotics, 
dyes, detergents, disinfectants, organic solvents, inhibitors of fatty acid synthesis and 
homoserine lactones involved in bacterial cell-to-cell signaling [40]. 
 The expression of outer membrane porins as well as efflux pumps is regulated by 
chromosomal loci. Two such loci are the marRAB operon or the mar locus and the soxRS 
operon. The mar locus consists of three genes namely marR (encoding a repressor protein 
MarR), marA (encoding a transcriptional activator MarA) and marB (encoding a protein 
with an unknown function). The soxRS operon encodes for two proteins namely SoxR (a 
regulator protein) and SoxS (a transcriptional activator) [35] . 
Expression of MarA produces an increase in the expression of micF, an antisense 
regulator that induces a posttranscriptional repression of the synthesis of OmpF. The 
soxRS operon also regulates the expression of micF [35].     
AcrR is a repressor protein of acrAB tolC encoded by the acrR gene, which is 
located immediately adjacent to the efflux genes. The mar locus is the most important site 
of mutations in E.coli that lead to multiple antibiotic resistance. MarR is a repressor of 
MarA, which in turn is a transcriptional activator of acrAB tolC. Therefore mutations 
leading to inactivation of marR or acrR result in up regulation of the efflux activity of the 
AcrAB TolC multidrug efflux pump [35, 40]. 
3.7.3 Transferable quinolone resistance: 
 In 1994 a novel gene named qnr located within an integron on the plasmid 
pMG252 was identified in a clinical isolate of Klebsiella pneumoniae [41-43]. This gene 
is associated with transferable multidrug resistance in gram-negative bacteria. The gene 
encodes for a protein (Qnr) of 218 amino acids belonging to the pentapeptide repeat 
family. Qnr confers low-level quinolone resistance by protecting the DNA gyrase from 
quinolone action. The exact mechanism is yet to be established. Recent studies have 
    
shown that there is a family of qnr proteins, all of which can cause low-level quinolone 
resistance. qnrA, qnrB and qnrS are proteins belonging to the family and possibly there 
are many other proteins yet to be discovered. The qnr gene has also been linked to the 
presence of extended spectrum or AmpC β-lactamases. The significance of qnr lies in its 
ability to increase the frequency of selection of chromosomal mutations leading to high-
level quinolone resistance [44].  
3.8. Bacterial efflux systems: 
 During the process of evolution bacteria have been exposed to a number of toxic 
products. As a protective mechanism they have developed unidirectional efflux systems, 
which catalyze the active extrusion of a number of structurally and functionally unrelated 
compounds from the cytoplasm to the exterior. This natural phenomenon often leads to 
multidrug resistance (MDR) [45] . 
Bacterial MDR pumps belong to four major families namely, 
1. The major facilitator super family (MFS) 
2. The small multi drug resistance (SMR) protein 
3. The ATP binding cassette and 
4. The resistance – nodulation - division (RND) family 
Recently a fifth family, the multi drug and toxic compound extrusion (MATE) family has 
been identified. The RND pumps are unique to the gram-negative bacteria. They are 
energy dependent and work in conjunction with a periplasmic membrane fusion protein 
(MFP) and an outer membrane protein (OMP). This organization facilitates the efflux of 
antibiotics across both membranes of the typical gram-negative cell wall [40, 45]. 
 The most important efflux system in E.coli is the AcrAB TolC system in which 
TolC protein is the OMP and AcrA is the MFP. It has been demonstrated that mutant 
    
strains, which manifest the organic solvent tolerance phenotype, are associated with 
enhanced transcriptional activity of the acrAB genes [40]. 
3.9 Epidemiology of FQR E.coli: 
 The advent of FQ was an important milestone in the history of antimicrobial 
therapy for UTI caused by gram-negative pathogens especially E.coli. Fluoroquinolone 
resistance among  E.coli was an uncommon phenomenon until a decade ago. Reports 
from all over the world suggest that the emergence of resistance to this important class of 
antibiotics has already begun and is increasing steadily. FQR E.coli have been reported in 
equal proportions from both hospital and community acquired infections. FQR is also 
frequently associated with multiple antibiotic resistance. This is a cause for great concern 
because it might ultimately limit the therapeutic utility of these agents. 
3.9.1 Prevalence of FQR E.coli: 
 FQR E.coli are being reported with increasing frequency from all parts of the 
world. Reports on FQR E.coli from various centers across United States and Canada have 
shown variable prevalence rates, with some centers reporting up to 25% [46, 47] . 
 A study on FQR E.coli from North America showed that the isolates were 
frequently associated with multidrug resistance. These isolates showed high rates of 
resistance to ampicillin (79.8%) and cotrimoxazole (66.5%). Resistance to nitrofurantoin 
(4%) was less frequent. All the isolates were susceptible to parenteral carbapenems [48]. 
 According to the Euro surveillance report 2006 the proportion of FQR E.coli 
isolates from Ireland increased from 5% in 2002 to 13% in 2004 and 17% in 2005 [49]. A 
study from Netherlands showed that norfloxacin resistance in E.coli increased from 1.3% 
in 1989 to 5.8% in 1998 with a concurrent increase in multidrug resistance from 0.5% in 
1989 to 4% in 1998 [50]. Susceptibility data of E.coli isolates from community acquired 
UTI in Greece showed a 36% resistance to ciprofloxacin [51]. 
    
A Latin American study on antimicrobial resistance of E.coli isolated from 
patients with UTI reported 24.5% resistance to ciprofloxacin [52]. A survey from 
hospitals in Taiwan revealed that 11.3% of E.coli isolates were resistant to FQ and 
another 21.7% had reduced susceptibility [53]. 
3.9.2 In India: 
 Reports on FQR E.coli from India are scanty. Data from our hospital show that 80 
to 90% of E.coli causing nosocomial UTI are resistant to ciprofloxacin while only 20% of 
E.coli causing community acquired UTI are similarly resistant. These isolates showed 
high rates of resistance to cotrimoxazole also [5]. 
 A study from Ludhiana during the year 1997-1998 showed that around 69-75% of 
E.coli isolated from UTI were resistant to ciprofloxacin and norfloxacin. More than 80% 
of these isolates were resistant to ampicillin and cotrimoxazole [54]. Another study from 
Bangalore during the year 1999 recorded 65.7%resistance to norfloxacin among E.coli 
isolated from UTI. The isolates also showed high level of resistance to ampicillin and 
cotrimoxazole [3]. 
 A study published in December 2001 reported 70-95% resistance to amoxicillin, 
cotrimoxazole, nalidixic acid, norfloxacin and ciprofloxacin among E.coli isolated from 
urine cultures [4]. 
 3.9.3 Risk factors for FQR: 
 FQ consumption, besides the underlying disease appears to be one of the most 
important risk factors. The highest resistance rates were found in nursing home residents 
where risk factors such as frequent use of quinolones, complicated infections and use of 
urinary catheters were commonly present [55, 56]. 
 Data from a study in Netherlands indicated that gender strongly influenced FQR 
probably on account of the different anatomic nature of the urinary tract in males and 
    
females. In women uncomplicated cystitis is the most common whereas in males 
complicated cystitis is more common for which they are likely to receive prolonged 
therapy with FQ, which may explain the relatively high resistance rates. Increased 
resistance is more common in older age groups because of increased cumulative exposure 
to the drug [50]. 
3.10 Extended spectrum β-lactamases: 
 β-lactamase production is the predominant cause of resistance to β lactam 
antibiotics in gram-negative bacteria [57]. The common β-lactamases are TEM1, TEM2 
and SHV1. Extended-spectrum β-lactamases (ESBLs) are a group of rapidly evolving  
β-lactamases that have the ability to hydrolyze the oxyimino- cephalosporins and 
aztreonam [57, 58]. These enzymes are inhibited by clavulanic acid and majority are 
variants that are derived through point mutations in the genes encoding for the common 
β-lactamases. The mutations lead to amino acid substitutions in the active sites of the 
TEM1, TEM2 or SHV1group of enzymes. Currently more than 150 different ESBLs have 
been described [59]. 
          The genes encoding ESBL production may be chromosomal or extra chromosomal. 
Extra chromosomal propagation is most commonly through plasmids but can also occur 
through transposons. Plasmids carrying genes encoding ESBLs may also carry genes 
encoding resistance to many of the aminoglycosides and cotrimoxazole [60, 61]. 
 The various phenotypic methods used for detection of ESBL are based on Kirby 
Bauer disc diffusion test methodology. The common techniques that are in use are the 
double disc approximation test [62], three-dimensional test described by Thomson and 
Sanders [63], Etest ESBL strips [64], disc diffusion test using commercially available 
antibiotic disc containing an expanded spectrum cephalosporin plus clavulanate and MIC 
performed with expanded spectrum cephalosporins with and with out the addition of 
    
clavulanic acid.  ESBLs can be characterized by molecular detection techniques including 
DNA probes, PCR, oligotyping, PCR - RFLP, PCR - SSCP, LCR and nucleotide 
sequencing [59]. Analytical isoelectric focusing (IEF) is a rapid method to assess the 
relative nature of β-lactamases present in a particular organism and a means for 
comparison of β-lactamases present in different organisms. However IEF alone cannot 
identify specific β-lactamases [65, 66]. 
 Infections caused by ESBL producing organisms are prone for treatment failures 
with expanded spectrum β-lactam antibiotics. According to NCCLS criteria any organism 
that is confirmed for ESBL production should be reported as resistant to all expanded 
spectrum beta lactam antibiotics regardless of the susceptibility test result [67]. 
3.10.1 ESBLs and Fluoroquinolone resistance: 
 Studies have shown that ESBL producing strains are more frequently associated 
with FQ resistance. In a study from Turkey it was demonstrated that ESBL producers 
were significantly more frequent among ciprofloxacin resistant E.coli strains than among 
ciprofloxacin susceptible E.coli [61]. Another Turkish study on intensive care and renal 
transplant patients reported that up to 40% of E.coli strains were ESBL producers and that 
the incidence of ciprofloxacin resistance among these strains was as high as 56% [68]. 
Possible explanations for FQR among ESBL producing E.coli are mutations in the mar 
locus and alterations in the outer membrane proteins. Further epidemiological and 
molecular studies are needed to understand the mechanisms involved in cross-resistance 
[61]. 
3.11 Typing systems: 
 Microbial epidemiologists monitor the spread of viruses, bacteria, fungi and 
protozoan parasites associated with human or animal infectious diseases at levels ranging 
from a single host or ecosystem to the worldwide environment. On the basis of 
    
epidemiological investigations, public health risks can be determined and interventions in 
the spread of diseases can be designed and their efficacy can be assessed [69]. 
 Epidemiological markers provide a means of distinguishing between different 
subgroups within the species and hence of addressing specific questions about the 
epidemiology of the diseases [70]. The methods used for typing the organisms can be 
classified as phenotypic and genotypic methods. Phenotyping procedures take advantage 
of biochemical, physiological and biological phenomena whereas genotyping aims to 
detect polymorphisms at the nucleic acid level. 
 3.11.1 Genotyping: 
Typing provides the means to discriminate between and catalogue microbial 
nucleic acids. The specific purpose of epidemiological typing includes study of bacterial 
population genetics, pathogenesis of infection, surveillance of infectious diseases and out 
break investigations [69]. 
In order to obtain meaningful epidemiological information from DNA finger 
printing methods, a genetic marker must give different patterns for epidemiologically 
unrelated strains and identical patterns for strains from a common source. 
For molecular typing of E.coli several different typing methods have been 
employed. These include ribotyping, ERIC PCR, RAPD and PFGE [71-73]. A 
comparative analysis of various typing method have shown that RAPD has the highest 
discriminatory capacity for typing E.coli isolates [71, 74]. 
3.11.2 RAPD: 
 
 RAPD is an amplification based DNA fingerprinting technique, which amplifies 
multiple targets on the genomic DNA to reveal polymorphisms [75]. It was first described 
by Williams et al in 1990 [76]. It is based on the use of short random sequence primers of 
9 to 10 base pairs in length. The rationale behind using such primers is that they are likely 
    
6 5 4 
to be complementary to many sites on the bacterial genome and many loci can be 
identified with a single primer [77]. The primer binds in an inverted orientation to two 
different sites on opposite strands of the DNA template at low annealing temperatures 
(Fig 3.2). If the sites of binding of the primers are close enough to each other, the 
intervening DNA is amplified during the cycles of PCR. The number and location of 
these random primer sites vary for different strains of bacterial species. Separation of the 
amplification products by agarose gel electrophoresis results in a pattern of bands 
characteristic of the particular strain [78, 79].  
 
Fig.3.2: Principle of RAPD 
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Fig 3.2 depicts the principle of RAPD. The arrows represent multiple copies of the 
same primer (same sequence). The direction of the arrow indicates the direction in which 
DNA synthesis will occur. The numbers represent locations on the DNA template to 
which the primers anneal. Primers anneal to sites 1, 2 and 3 on the top strand and to sites 
4,5 and 6 on the bottom strand of the DNA template. 
2 3 
A B
1 
    
 Product A is produced by PCR amplification of the DNA sequence which lies in 
between the primers bound at positions 2 and 5. Product B is produced by PCR 
amplification of the DNA sequence, which lies in between the primers, bound at positions 
3 and 6.Therefore the same primer will produce multiple products of different molecular 
weight. No PCR product is produced by the primers bound at positions 1 and 4 because 
these primers are too far away to allow the completion of the PCR reaction. Similarly no 
PCR product is produced by the primers bound at positions 5 and 3 because these primers 
are not oriented towards each other. 
 The relatedness of the isolates is assessed based on the genetic between each 
other. This is done using computer programme like RAPDistance programme. This 
programme generates data based on the sizes, and the presence or absence of shared 
bands. The primary data is then used to calculate the pair wise distance between the 
samples using one of the various metrics like the coefficient by Jaccard or Dice [80] . 
Using the distance data thus obtained phylogenetic trees can be constructed. Some of the 
methods that are used for tree construction are the unweighted pair group method of 
analysis, Farris’s method, Sattath and Tversky’s method, Li’s method, Tateno et al.‘s, 
modified Farris method and the neighbour joining method. The neighbour joining (NJ) 
method, which was first described by Saitou and Nei (1987) and later modified by Studier 
and Kepler (1988), has been shown to be an efficient and reliable method for analyzing 
bands obtained in RAPD of strains within a species. This method seeks to build a tree that 
minimizes the sum of all edge lengths, i.e., it adopts the minimum evolution criterion. It is 
applicable to any type of evolutionary distance data [81, 82]. 
RAPD is easy to use and interpret. The sample preparation is much less laborious 
because only a very small amount of DNA is required. The procedure can be performed 
with a universal set of primers without the need for probe isolation, filter preparation or 
    
nucleotide sequencing. Studies have shown that the polymorphisms with in a species can 
be identified using even a small number of primers [76]. Mulcahy et al has reported that a 
single primer is often sufficient to study the polymorphism [83]. The presence of single 
point mutations in the genome can also be identified by this method. The assay can be 
automated [84]. It has a high discriminatory power and the cost per test is low. The result 
can be obtained in a day and is reliable [78]. The method has the potential for analyzing 
phylogenetic relationship among closely related species and can distinguish between 
strains within a species [85]. It is also a valuable tool in the genetic analysis of organisms 
whose genome has not been described completely [76].  The availability of RAPD has 
provided a valuable approach in genotyping E. coli [71]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
MATERIALS AND METHODS
    
    E.coli isolated from routine urine cultures were further evaluated to understand 
more details about Fluoroquinolone resistance (FQR), like its association with other 
antimicrobial resistance (AMR) and the possible mechanisms involved in causing FQR. 
The clonal relatedness of the isolates were also studied. The protocol followed is 
summarized in figure 4.1.Detailed methodology is given below.   
4.1 Sample size: 
The expected prevalence of strains with up regulated efflux pumps was taken, as 
60% based on data published from Sweden [9] since there is no data from India. The 
sample size for the organic solvent tolerance test was calculated as 343 by using the 
formula, 
n = (Zα +Z1 -β)2 2PQ \ d2     
n = 10.3 × 2 × 60 × 40 \ 12 × 12 = 343 
Zα =1.96, Z1 -β = 2.58   
P = Expected prevalence of strains with efflux pumps. 
            d = Absolute difference (12%). 
Q = 1- P.  
The same isolates were used to study other AMR in E.coli, including ESBL.  
A sample size of 120 strains was chosen for RAPD typing, which included a 
minimum sample size of 30 strains in each category. A sample size of 30 would give us 
enough information to conclude whether the strains belonged to single or multiple clones. 
It would also enable us to obtain information on the predominant genotypes in the 
hospital setting and in the community. This method of an acceptable sample size in each 
category was followed since there was no data on the clonal characteristics of FQR E.coli 
from India. 
 
    
Fig.4.1: Flow chart showing selection of samples and methods followed. 
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4.2 Bacterial isolates: 
4.2.1 Collection: 
E.coli obtained from routine urine cultures during the period from September 
2004 to December 2005 in the Department of Clinical Microbiology, Christian Medical 
College Hospital, Vellore were included in the study. 
 Pure growth of E.coli obtained in counts of ≥104CFU /ml were considered as those 
causing urinary tract infections (UTI). Those isolated in counts of < 1000 CFU/ ml along 
with other organisms were considered as commensals.  The E.coli were identified based 
on their ability to grow on Maconkey agar, oxidase negativity, biochemical reactions in 
triple sugar iron agar and mannitol motility medium, ability to produce indole, ferment 
sorbitol and inability to utilize citrate. 
Antimicrobial susceptibility testing was done routinely by Kirby Bauer method by 
following CLSI criteria strictly. Those E.coli that were resistant to norfloxacin (10µg/ml 
Span diagnostics, Surat, India) were selected for further study. The organic solvent 
tolerance test was done on all 343 isolates thus selected to detect the presence of efflux-
mediated resistance. MIC of nalidixic acid (Pure substance, Himedia, Mumbai, India) was 
determined for 60 strains consisting 30 each of community acquired and hospital acquired 
strains. MIC of nalidixic acid was also determined for 30 fluoroquinolone susceptible but 
nalidixic acid (30µg/ml, Span Diagnostics, Surat India) resistant strains. To understand 
the prevalence of resistance to other antimicrobials among FQR strains, data on 
susceptibility to other antibiotics were collected. Those isolates with <27mm zone size for 
cefotaxime (30µg/ml, in-house preparation, pure substance from Sigma USA) were 
subjected to double disk diffusion to detect ESBL production.  
To understand the clonal relatedness, a subset of thirty resistant strains each 
isolated from urology in-patients with hospital acquired UTI and from antenatal women 
    
and medicine outpatients with community acquired UTI were subjected to RAPD 
analysis.  Thirty isolates of E.coli, which were susceptible to norfloxacin and thirty 
isolates of commensal E.coli, which were resistant to norfloxacin, were also subjected to 
the same test. 
4.3 Organic solvent tolerance test for identifying isolates with up-regulated efflux: 
 The organic solvent tolerance test is a phenotypic test that correlates positively 
with the presence of an efflux mediated antimicrobial resistance. The test was performed 
as follows using hexane and cyclohexane as the organic solvents [9, 86, 87]. 
4.3.1 Preparation of media: 
 The LBGMg agar, which consists of Luria agar (Appendix 1), 0.1%glucose and 
10mM of MgSO4 prepared in glass petri dishes, was used for the test.  
4.3.2 Preparation of bacterial suspension: 
E.coli were subcultured on blood agar to obtain pure growth and then suspended 
in 0.5 ml of 0.9% sterile NaCl to match 0.5 McFarland approximately. 
 E.coli MG1655 was used as a control strain that grew on hexane but not on 
cyclohexane. Two in house controls, one positive and one negative for efflux were also 
chosen from the test strains, to be included in each batch of test done. 
4.3.3 Procedure: 
 Five plates of LBGMg medium were prepared and 5µl each of the bacterial 
suspensions were spot inoculated on all the plates using a template as for MIC testing.  
The first plate was used as a control plate. The second plate was overlaid with pure 
hexane. The other three plates were overlaid with a mixture of hexane and cyclohexane in 
the ratio of 3:1, 1:3 and 1:1 respectively. The solvents were overlaid to a thickness of 
3mm uniformly. The plates were sealed and incubated at 37ºC for 16 to 18 hours. 
 
 
    
4.3.4 Reading and interpretation:  
The plates were read after 18 hours of incubation. The control plate was read first 
to ensure that there is adequate growth of all the isolates. Then, the readings for the 
control strains were taken from the organic solvent overlaid plates. Confluent growth 
occurring in the presence of hexane and cyclohexane in 1:1 ratio was taken as organic 
solvent tolerance. This is indicative of an up-regulated AcrAB-TolC efflux pump 
mechanism. The readings from the other plates (1:3 and 3:1) were used to correlate with 
the readings on the 1:1 plate. 
4.4 Antimicrobial resistance: 
4.4.1 Minimum Inhibitory Concentration (MIC) of nalidixic acid: 
 The degree of resistance to nalidixic acid can be used to understand the mutations 
in gyrA. A high MIC of > 256 mg/ml is usually indicative of a mutation at codon 83 or 
multiple stepwise mutations [9].  
a) Preparation of antibiotic solution:  
This is described in Appendix 2.  
b) Preparation of media: 
 Mueller-Hinton Agar (MHA) was used for agar dilution. MHA medium (18ml) 
was prepared in tubes, autoclaved and allowed to cool to 50ºC. Diluted (to obtain 
concentrations of 256 –0.025μg/ml) antibiotic solution (2ml) was added to the molten and 
cooled medium in each tube. The contents were mixed well and poured into petri dishes. 
A control plate of the medium without the antibiotic was prepared for each day of testing.  
 c) Preparation of the inoculum: 
 The inoculum was an actively growing culture of about 104 microorganisms per 
ml. In order to achieve this 3 to 5 well-isolated colonies of the test strain were touched 
with a loop and inoculated into 0.5 ml of nutrient broth and incubated at 37ºC for 2 hours. 
    
The turbidity of the actively growing broth culture was adjusted to 0.5 McFarland 
standard and then diluted 1 in 10 in sterile normal saline.  
 d) Inoculation of the test plates: 
 A platinum loop calibrated to deliver 0.001 ml of the inoculum was used to spot 
inoculate the plates. Each spot was about 5 to 8mm in size. After the inoculum had dried 
the plates were inverted and incubated at 37ºC for 16 to 18 hours. E.coli ATCC 25922 
was used as the control strain. 
 e) Reading and Interpretation: 
 The control plate was read first to ensure adequate growth of all the test strains. It 
was verified whether the MIC of the control strain was in the expected range. The lowest 
concentration of the antimicrobial that completely inhibited the growth was considered 
the end point. A barely visible haziness or a single colony was disregarded. Results were 
reported as µg/ml. CLSI interpretative criteria for MIC determination was used to define 
susceptibility categories [67].  
4.4.2 Double disk diffusion: 
 Of the 343 isolates of E.coli, those which showed <27mm zone size for 
cefotaxime (30µg/ml), were subjected to double disk diffusion. 
a) Preparation of the inoculum: 
 Well-isolated colonies (3-5 no.) of the test strain were touched with a loop and 
inoculated into 0.5 ml of nutrient broth and incubated at 37ºC for 2 hours. The turbidity 
of the actively growing broth culture was adjusted to 0.5 McFarland standard with sterile 
normal saline.  
 b) Control strains: 
 Klebsiella pneumoniae ATCC 700603 and E.coli ATCC 25922 were used as 
positive and negative controls respectively. 
 
    
 c) Inoculation of the test plates and application of the antibiotic discs: 
 The standardized inoculum was streaked on Mueller-Hinton Agar (MHA) to 
obtain a lawn culture. Two discs namely Cefotaxime-clavulanic acid (30µg/ml and 
10µg/ml Becton and Dickson, USA) and Cefotaxime (30µg/ml,in house preparation) 
were  applied to the culture at an approximate distance of 2mm from each other and 
incubated at 37ºC for 16 to 18 hours. 
 d) Reading and Interpretation: 
 A relative increase in the cefotaxime-clavulanic acid zone diameter of > 3mm in 
comparison with cefotaxime alone was considered to be indicative of ESBL production in 
the test strains. Readings of test strains were taken if the control strains gave acceptable 
results. 
4.4.3 AMR to other antibiotics: 
Data on susceptibility to a panel of antibiotics including cotrimoxazole, 
nitrofurantoin, cephalosporins and aminoglycosides were collected, in order to understand 
the prevalence of resistance to other antimicrobials among FQR strains.  
4.5 Genotyping by RAPD: 
 The protocol of Pacheco et al was used for RAPD typing [88]. A total of 120 
isolates of E.coli were typed by this method and analyzed. NU14 and ATCC E.coli 25922 
were used as control strains. 
 4.5.1 Extraction of chromosomal DNA: 
 The isolates were grown on sheep blood agar for 16 to 18 hours and the cells were 
suspended in 100µl of milliQ water. The cell suspension was boiled for 2 minutes at 
100ºC in a water bath and centrifuged at 12,000 rpm for 1 minute. The supernatant was 
used as the DNA template. 
 
 
    
4.5.2 Procedure: 
 The PCR was carried out with two primers separately. The primers used were 
1254 (5’ – CCGCAGCCA – 3’) and 1290 (5’ – GTGGATGCGA – 3’). The reactants 
were constituted to 30µl volumes with 20mM Tris HCl (pH 8.4), 50mM KCl, 3mM 
MgSO4, 250 µM each of dNTPs, 30pmol of primer, 1unit of Taq polymerase and 3µl of 
bacterial lysate. 
 Temperature cycling was controlled in a thermal cycler (PTC – 100 DNA Peltier 
thermal cycler, MJ Research, USA.). The thermal cycler was programmed for 
denaturation at 94ºC for 5 minutes, annealing at 37ºC for 5minutes,extension at 72ºC for 
5 minutes followed by 30 cycles of 94ºC for 1 minute, 37ºC for 1 minute, 72ºC for 2 
minutes and a final extension step at 72ºC for 10 minutes. Amplified products were 
subjected to electrophoresis at 100volts for 90 minutes in a 1.2% agarose gel containing 
0.5µg/ml of ethidium bromide. DNA ladder (gene ruler – 100bp) was used as molecular 
weight marker. Gel pictures were made.  
4.5.3 Analysis of RAPD data: 
 From the gel pictures the number of bands and their respective positions were 
recorded for both primers. This information was entered into the RAPDistance program 
version 1.04. The relatedness of the isolates was calculated by the program based on the 
number of shared bands and the number of unique bands in each isolate. A matrix of pair 
wise differences was prepared using the Jaccard coefficient (S = a/(a+b+c) where “a” is 
the number of shared bands between samples 1 and 2, “b” is the number of bands present 
in sample 1 but not in 2 and “c” is the number of bands present in sample 2 but not in 1) 
in the same program. This matrix was used to construct a dendrogram using the NJTREE 
program [81, 82]. 
 
    
                            
 
 
 
 
 
                                   RESULTS
    
           Three hundred and forty three strains of E.coli resistant to norfloxacin isolated 
from urine samples were used for the study. All the strains were resistant to nalidixic acid 
and all except two were resistant to ciprofloxacin.   
5.1 Antimicrobial resistance among fluoroquinolone resistant (FQR) E.coli: 
The antibiotic susceptibility profile of the strains to a panel of antibiotics 
including nitrofurantoin, cotrimoxazole, gentamicin, amikacin, netilmicin, cefuroxime 
and cefotaxime were analyzed. The results are summarized in Table-1. 
                       Table - 5.1: Antibiotic susceptibility profile of FQR E.coli. 
Antibiotic Resistant Sensitive 
No. % No. % 
Nitrofurantoin 104 30.3 239 69.7 
Cotrimoxazole 287 83.7 56 16.3 
Gentamicin 228 66.5 115 33.5 
Amikacin 125 36.4 218 63.6 
Netilmicin 114 33.2 229 66.8 
Cefuroxime 242 70.6 101 29.4 
Cefotaxime 219 63.8 124 36.2 
 
 Among the antimicrobials tested, maximum susceptibility was to nitrofurantoin 
(69.7%). This was higher than that to netilmicin (66.8%) and amikacin (63.6%). A high 
percentage of isolates were resistant to cotrimoxazole (83.7%) followed by cefuroxime 
(70.6%) and gentamicin (66.5%). In comparison only 43.3% of the fluoroquinolone 
susceptible strains were resistant to cotrimoxazole (Table – 5.2) and majority of the 
strains were susceptible to nitrofurantoin, gentamicin and cefuroxime. Forty percent of 
fluoroquinolone susceptible strains were resistant to nalidixic acid. The difference in the 
prevalence of AMR to nitrofurantoin, cotrimoxazole, gentamicin and cefuroxime between 
FQR and fluoroquinolone susceptible E.coli is statistically significant (p value was 
calculated using the Statcalc programme of the Epi info version – 3.2.2).  
 
    
Table – 5.2 Antibiotic susceptibility profile of Fluoroquinolone susceptible E.coli (n=30). 
Antibiotic Resistant Sensitive *P value 
No. % No. % 
Nitrofurantoin 1 3.3 29 96.7 0.002 
Cotrimoxazole 13 43.3 17 56.7 <0.001 
Gentamicin 2 6.7 28 93.3 <0.001 
Cefuroxime 1 3.3 29 96.7 <0.001 
Nalidixic acid 12 40 18 60 <0.001 
 
* Compared to FQR E.coli 
5.1.1 Aminoglycoside resistance among FQR E.coli    
A total of 228 isolates were resistant to gentamicin of which 54.9% and 50% were 
resistant to amikacin and netilmicin respectively (Table –5.3). 
                                  Table – 5.3: Resistance to aminoglycosides. 
Isolates resistant to gentamicin n=228 
Antibiotic Resistant Susceptible 
No. % No. % 
Amikacin 125 54.9 103 45.1 
Netilmicin 114 50 114 50 
 
5.1.2 Extended spectrum β – lactamases (ESBL) among FQR E.coli  
 Out of the 343 isolates analyzed, 237 strains (69.1%) showed a zone size of < 
27mm to cefotaxime. Among the 237 strains 219 (63.9%) showed a zone size of < 23mm 
and were designated as resistant to cefotaxime according to NCCLS criteria. All the 
resistant strains except two (99.1%) were positive for ESBL by double disc diffusion. 
None of the strains with zone sizes between 23 and 27mm were ESBL producers (Table 
5.4). In the FQ susceptible group only one isolate showed cephalosporins resistance and 
ESBL production. (p= < 0.001). 
    
                                       Table – 5.4 ESBL among FQR E.coli: 
 
Cefotaxime 
Zone size 
(mm) 
ESBL 
Positive Negative 
No. % No. % 
< 23 217 99.1 2 0.9 
23 - 27 - - 18 100 
 
 
5.2 Efflux mediated resistance among FQR E.coli: 
 Among the 343 isolates subjected to the organic solvent test, 137 (39.9%) isolates 
were positive, indicating up-regulated efflux pumps (fig.5.1).  
 
  
Fig.5.1 Efflux mediated resistance 
among FQR E.coli
60.1%
39.9%
         Efflux positive
         Efflux negative
                                         
  
The tolerance shown by the FQR E.coli to various proportions of hexane and 
cyclohexane in the organic solvent tolerance test (fig. 5.2, 5.3, 5.4, 5.5, 5.6) is shown in 
Table – 5.5. Only those strains, which were able to grow in the presence of hexane and 
cyclohexane in the ratio of 1:1, were considered as efflux positive. Among the efflux 
positive strains, all grew in the presence of pure hexane and hexane/cyclohexane in the 
    
ratio of 3:1. Growth was found in 14.6% of the strains even when the concentration of 
cyclohexane was increased to 1:3 ratio. None of the efflux negative strains grew in the 
presence of hexane/cyclohexane in 1:1 ratio. 
 
Table – 5.5 Organic solvent tolerance 
   
 
  
   
 
5.2.1 Association of efflux pumps with resistance to other antibiotics  
The association of efflux pumps with other AMR is shown in Table – 5.6. 
                                                          Table 5.6 
 
 
Antibiotic Efflux P value 
Positive Negative 
No. % No. % 
 
Nitrofurantoin 
Susceptible 83 60.6 156 75.7 0.002 
Resistant 54 39.4 50 24.3 
 
Cotrimoxazole 
Susceptible 23 16.8 33 16 0.85 
Resistant 114 83.2 173 84 
 
Gentamicin 
Susceptible 39 28.5 76 36.9 0.1 
Resistant 98 71.5 130 63.1 
 
Amikacin 
Susceptible 79 57.7 126 61.2 0.51 
Resistant 58 42.3 80 38.8 
 
Netilmicin 
Susceptible 87 63.5 133 64.6 0.84 
Resistant 50 36.5 73 35.4 
 
Cefuroxime 
Susceptible 26 18.9 75 36.4 <0.001 
Resistant 111 81.1 131 63.6 
 
Cefotaxime 
Susceptible 37 27 87 42.2 0.004 
Resistant 100 73 119 57.8 
 
 
 
 
Organic solvent 
tolerance 
Hexane: Cyclohexane ratio 
Pure 
hexane 
3:1 1:1 1:3 
Positive (n=137) 137 137 137 20 
Negative(n=206) 50 18 0 0 
    
AMR to nitrofurantoin, cefuroxime and cefotaxime was more among the efflux 
positive strains when compared to the efflux negative strains and the difference was 
statistically significant. Aminoglycoside resistance was not significantly different in 
efflux positive and efflux negative groups. 
5.2.2 Susceptibility patterns of efflux positive and efflux negative FQR E.coli  
 Out of the 343 strains only 14 strains were resistant to fluoroquinolones alone of 
which 12 strains (86%) were efflux negative (p=0.006) (Table - 5.7). However multiple 
AMR i.e. resistance to three or more different groups of antibiotics was found to be more 
among the efflux positive strains (p <0.001). Among the efflux positive strains 119 of the 
137 strains (86.9%) showed multiple antibiotic resistance. In comparison, 71.4% of the 
efflux negative strains showed multidrug resistance. The commonest MDR was to 
cephalosporins, cotrimoxazole and aminoglycosides amongst both efflux positive and 
efflux negative isolates. MDR, which includes cephalosporins, was found in 107 (78.1%) 
of the efflux positive strains compared to 127(61.7%) in the efflux negative group.  
The incidence of MDR among FQR isolates was significantly high when 
compared to the fluoroquinolone susceptible strains (Table 5.8). The difference was 
statistically significant (p value <0.001).    
 
 
 
 
 
 
 
 
    
 
Table – 5.7 
 
Antibiotics 
Efflux positive 
(n=137) 
Efflux negative 
(n=206) 
No. % No. % 
Fluoroquinolones (FQ) alone 2 1.5 12 5.8 
FQ + Cephalosporins 2 1.5 4 1.9 
FQ + Aminoglycosides 4 2.9 3 1.5 
FQ + Cotrimoxazole 8 5.8 38 18.5 
FQ + Nitrofurantoin 2 1.5 2 1 
FQ + Cephalosporins + Aminoglycosides 9 6.6 10 4.9 
FQ + Cephalosporins + Cotrimoxazole 12 8.8 14 6.8 
FQ + Cephalosporins+ Nitrofurantoin 1 0.7 0 0 
FQ + Cephalosporins + Cotrimoxazole + 
Nitrofurantoin 
6 4.4 2 1 
FQ + Cephalosporins + Cotrimoxazole+ 
Aminoglycosides 
51 37.2 62 30 
FQ + Cephalosporins+ Nitrofurantoin+ 
Aminoglycosides 
0 0 2 1 
FQ + Cephalosporins + Cotrimoxazole+ 
Aminoglycosides + Nitrofurantoin 
28 20.4 37 18 
FQ + Cotrimoxazole+ Nitrofurantoin 4 2.9 4 1.5 
FQ + Cotrimoxazole+ Aminoglycosides 4 2.9 13 6.3 
FQ + Cotrimoxazole+ Nitrofurantoin+ 
Aminoglycosides 
4 2.9 3 1.5 
 
 
 
 
 
 
    
Table 5.8 
 
 
 
 
 
 
* Efflux positive Vs Efflux negative 
** FQR Vs FQ susceptible 
5.2.3 Efflux in different populations: 
Presence of efflux pumps in two groups of isolates viz. one from hospital-acquired 
infections and the other from community-acquired infections were compared (Table – 
5.9). 
Table – 5.9 
Strains Efflux positive Efflux negative 
No. % No. % 
Community acquired (n = 30) 12 40 18 60 
Hospital acquired (n = 30) 13 43.3 17 56.7 
  
Efflux positivity was found in 40% of community acquired and 43.3% of the hospital-
acquired strains. The difference is not statistically significant (p= 0.79). 
5.3 Minimum inhibitory concentration for nalidixic acid as a phenotypic marker of 
gyrA mutations: 
MIC for nalidixic acid was determined for 60 FQR strains 30, each from 
community acquired infections and hospital-acquired infections respectively. Fifty-nine 
of them had MIC above 256μg/ml. MIC was also done on 30 nalidixic acid resistant and 
fluoroquinolone susceptible isolates (Table 5.10). 
Strains Multi drug resistance P value 
No. % 
FQR 
(n=343) 
Efflux positive 119 86.9 <0.001* 
Efflux negative 147 71.4 
FQ susceptible  (n=30) 1 3.3 <0.001** 
    
Table – 5.10 
 
 
 
 
 
 
 
 
5.4 Relationship between different groups of isolates by RAPD: 
 A total of 120 isolates consisting of four populations of 30 each were typed by 
RAPD to determine the genetic relatedness among the strains. The four populations 
consisted of 30 fluoroquinolone susceptible E.coli and 30 each of fluoroquinolone 
resistant E.coli from community acquired and hospital acquired infections and 
commensals. The RAPD profile of each isolate was obtained using two PCRs with 
primers 1254 and 1290. The protocol produced discrete well-resolved bands in all runs 
included for analysis (fig. 5.7, 5.8, 5.9, 5.10). The controls ATCC E.coli 25922 and E.coli 
NU14 gave reproducible results in each run. When the primer 1254 was used, the bands 
generated by the amplified products consisted of 15 bands overall with a minimum of 1 
and a maximum of 9 bands. With the primer 1290, 16 unique bands were obtained with a 
minimum of 1 and a maximum of 10 bands. Therefore relatedness was calculated based 
on 31 bands. The molecular weights of the bands ranged from 200bp to 5000bp. 
5.4.1 Analysis of genotypes: 
 Dendrograms constructed using the NJTREE (neighbor- joining tree) software 
(fig. 5.11, 5.12, 5.13, 5.14) showed that many different RAPD types existed among the 
isolates.  There was very little homology between the strains with only two or three 
isolates being identical with each other.  
Isolates No. of 
isolates 
tested 
MICμg/ml 
32 64 128 >256 
 
 
FQR 
 
 
 
Community acquired 
 
Hospital acquired 
 
 
30 
 
- 
 
- 
 
- 
 
30 
 
30 
 
- 
 
- 
 
1 
 
29 
 
FQ susceptible 
 
30 
 
1 
 
2 
 
15 
 
12 
    
a) Fluoroquinolone susceptible E.coli: 
 Twenty-seven RAPD types were identified among the fluoroquinolone susceptible 
E.coli. Of the final right and left neighbors the right had 24 (80%) isolates. In this group 
19 isolates belonged to a single sub branch. Three isolates in this branch were identical. 
The minimum distance from the root was 0.281 and the maximum distance was 0.448. 
Fig. 5.11: Dendrogram of fluoroquinolone susceptible E.coli 
 
 
 
 
 
1 
2 
    
b) Commensal FQR E.coli: 
 Among the commensal E.coli 29 RAPD types were found. Here again the right 
branch had 24 (80%) isolates of the 30. Twenty isolates (73 %) belonged to a single sub 
branch in the right branch. Two isolates in the smaller group were identical. The 
minimum distance from the root was 0.319 and the maximum distance was 0.512. 
Fig. 5.12: Dendrogram of commensal FQR  
 
 
 
 
1 
    
c) Community acquired FQR E.coli 
 All 30 isolates in the community-acquired group gave unique RAPD patterns. The 
right and the left branches in the NJTree had 22 and 8 isolates each. Within these two 
groups all isolates were at distances of >0.121. The minimum distance from the root was 
0.338 and the maximum distance was 0.501. 
Fig. 5.13: Dendrogram of community acquired FQR E.coli 
 
 
 
 
 
 
    
d) Hospital acquired FQR E.coli: 
  Twenty-nine RAPD types were identified in this group. In this group the right and 
the left branches had 13 and 12 isolates each. There were two identical isolates and a third 
at a distance of 4% from them. Another two isolates were at a distance of 0.06 (1 and 16). 
Apart from these, all the isolates were at a distance of 10% or further from each other. 
With the exception of these two clusters with a total of 5 isolates all the other isolates 
were different from each other. The minimum distance from the root was 0.316 and the 
maximum distance was 0.469. 
Fig. 5.14 Dendrogram of hospital acquired FQR E.coli 
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2 
13 
    
Comparison of isolates belonging to different categories showed that the isolates 
from commensal and community acquired infections did not belong to separate groups. 
The isolates were scattered throughout the tree. A similar pattern was observed with 
commensal and hospital acquired E.coli. 
 Distinctive groups were seen on comparing the FQR commensal E.coli with the 
fluoroquinolone susceptible E.coli. Twenty of the 30 fluoroquinolone susceptible E.coli 
were at the right branch. The same difference was seen on comparing the fluoroquinolone 
susceptible E.coli and the FQR hospital acquired E.coli. All the fluoroquinolone 
susceptible isolates fell into one arm, while the FQR hospital acquired E.coli fell into the 
other arm. Similarly the distribution of fluoroquinolone susceptible E.coli and the 
community acquired FQR E.coli in the dendrogram showed that they were genetically 
different. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
                    DISCUSSION
    
        Fluoroquinolones are used for various indications and in large quantities worldwide. 
Their introduction in to clinical use marked the beginning of a new era in the treatment of 
urinary tract infections and other infections caused by gram-negative bacteria [89]. 
Excellent therapeutic efficacy, broad spectrum of activity, good bioavailability, low cost 
and fewer side effects led to their widespread use both in the hospitals and in the 
community [11, 12]. Ongoing research and better understanding of the chemical structure 
and mechanisms of action have led to the development of newer compounds with wider 
spectrum of activity, improved pharmacokinetic properties and favorable side effect 
profile. In the current scenario, fluoroquinolones are being used increasingly in the 
treatment of almost all types of infections including those caused by gram-negative and 
gram-positive bacteria, anaerobes and even mycobacteria. 
At the time of their introduction it was believed that the potential for developing 
resistance to these agents among enterobaceriaceae was very low. Rampant use and 
misuse of these antimicrobial agents over the last decade has led to the emergence of 
resistance [56]. Fluoroquinolone resistant E.coli are being reported from all parts of the 
world [48-53]. Data from our hospital have shown 20 to 22% resistance among E.coli 
causing community acquired UTI and 70 to 90% resistance among those causing hospital-
acquired UTI. [5].  
 Emergence of FQR E.coli is a potential threat to the therapeutic utility of this 
important class of antimicrobials in the treatment of UTI. Knowledge on the prevalence 
and distribution of FQR E.coli and the mechanisms involved in the development of 
resistance are indispensable to design specific interventions to limit dissemination.  
 The principal mechanisms involved in FQR are alterations in the target enzymes 
and decreased intracellular concentration of the drug due to impermeability of the outer 
membrane and/or up regulated efflux pumps. Both are primarily mediated through 
    
chromosomal mutations [35]. The change from susceptible phenotype to resistant 
phenotype requires several stepwise mutations [8, 38]. Single mutations most often do not 
produce resistance [9].  
A high level of resistance (MIC >256 μg/ml) to nalidixic acid is predictive of 
mutations at codon 83 of gyrA. Ninety seven percent of high nalidixic acid resistant 
isolates have been found to possess this mutation [9]. All 60 FQR E.coli tested in the 
study showed high-level resistance to nalidixic acid. Twenty seven (90%) of 
fluoroquinolone susceptible E.coli also showed high-level resistance to nalidixic acid. 
FQR E.coli commonly have additional mutations in gyrA and probably parC. A Swedish 
study has reported that 87% of FQR E.coli had mutations at two loci responsible for 
codon 83 and 87 of gyrA and that mutations in both gyrA and parC were found in 77% of 
resistant isolates [9]. Since 30% of community acquired infections and 90% of hospital-
acquired infections are FQR it can be assumed that a good proportion of our E.coli 
causing UTI carry several mutations. This may be applicable to E.coli causing other 
infections also. The presence of high MIC to nalidixic acid in 90% of fluoroquinolone 
susceptible but nalidixic acid resistant strains indicates that these strains may probably 
carry gyrA mutations at codon 83. Treatment of infections caused by such “susceptible” 
strain with fluoroquinolones can lead to more mutations and rapid evolution and selection 
of FQR strains. It is therefore prudent to test for nalidixic acid resistance and limit the use 
of fluoroquinolones if the E.coli are found to be resistant. 
 The second mechanism, which leads to decreased intracellular 
concentration of the antibiotic, is also mediated by chromosomal mutations, leading to 
up-regulation of some efflux pumps and decreased expression of outer membrane 
proteins like the ompF [35]. Of the 343 isolates 137(40%) were positive for an up-
    
regulated efflux. This shows that at least 40% of the strains have both mechanisms of 
resistance for FQR. This again is an indication of multiple chromosomal mutations [9].  
 Efflux pumps are transport proteins involved in the extrusion of toxic substrates 
from within cells into the external environment [45]. Several such efflux pumps have 
been described in E.coli but the most important among them is the AcrAB-TolC [40]. 
Over expression of this efflux pump is usually the result of mutations in the marR locus, 
which is a repressor gene [35]. Increased efflux activity results in the ability to extrude 
organic solvents and thus tolerance to these chemicals.  Hence this method was used as a 
phenotypic marker for up-regulated efflux pumps [9]. Organic solvent tolerance test is a 
simple test, which is easy to perform even in small laboratories and the cost per test is 
low. The test is usually performed using glass petri dishes because the solvents used in 
the test can dissolve plastic. Efflux positive E.coli have shown the ability survive under 
such adverse conditions. Besides hexane and cyclohexane the test can also be performed 
using other organic solvents like diphenyl ether, and p-xylene [86]. The importance of 
detecting efflux-mediated resistance is that it is often associated with multiple antibiotic 
resistance [35, 40]. 
 Studies have reported increased mutational rates in FQR E.coli. FQR E.coli are 
mostly intermediate mutators, which show a mutational rate of about 10 times more than 
that of susceptible isolates [9]. Strong mutators with mutS, which have 100 times more 
mutating potential, have also been described [90, 91]. The mutator allele can be co-
selected by antibiotic treatment [92]. Even though strong mutators promote the rapid 
evolution of resistance they have a low survival rate due to accumulation of other 
deleterious mutations also. Strains with intermediate mutational rates, which are strongly 
associated with FQ resistance, probably have better survival chances. This is in agreement 
with the mathematical analysis of mutator dynamics in fluctuating environment [93]. 
    
The practical implication is that antimicrobial treatment of strains with high 
mutation rate can lead to selection of resistant strains rapidly. Strains, which are likely to 
mutate, can be identified by nalidixic acid MIC. Presence of high-level resistance to 
nalidixic acid indicates that mutations already exist and exposure to antimicrobials can 
lead to rapid development of further resistance by mutations [9, 35]. Ninety eight percent 
of FQR E.coli and 90% of fluoroquinolone susceptible E.coli showed a MIC of > 
128µg/ml with nalidixic acid. 
In our study 329 (96%) of the 343 FQR isolates had resistance to other antibiotics. 
This is significantly different from the AMR seen in fluoroquinolone susceptible strains. 
On analyzing the presence of other AMR in efflux positive isolates it was found that these 
strains were more frequently associated with resistance to multiple antimicrobials like 
cephalosporins, aminoglycosides, cotrimoxazole and nitrofurantoin. On considering 
individual drug groups resistance to cephalosporins and nitrofurantoin were significantly 
associated with a positive efflux. A similar association was not found with 
aminoglycoside resistance. Even though multiple antimicrobial resistance was found 
among both efflux positive and efflux negative FQR E.coli the percentage was higher in 
efflux positive strains (pvalue = 0.001). Among the efflux positive strains 87% showed 
resistance to multiple antibiotics where as only 71% of the efflux negative strains were 
multidrug resistant. In contrast among the 30 FQ susceptible strains tested in our study, 
only one strain exhibited multidrug resistance. It appears as though FQR strains have the 
potential for acquiring other resistances.  This in agreement with previous published 
papers, which have shown that resistance to antibiotics like ampicillin and nalidixic acid, 
may be the starting point for acquiring multidrug resistance [60, 94]. Although efflux 
pumps appear to play a role, this is not the only mechanism for MDR in our area. 
    
Tests revealed that 64% of FQR E.coli were resistant to cefotaxime and 99% 
percent of them were ESBL producers. The evolution of ESBL is usually through 
mutations in the plasmid genes encoding for the earlier broad-spectrum beta lactamases 
like TEM –1, TEM-2 and SHV-1. ESBL production was significantly more in FQR E.coli 
when compared to the susceptible strains in other studies also [61]. Since ESBL genes are 
carried on plasmids the reason for this association is not clear. There are reports showing 
that ESBL may also be chromosomally mediated [61]. The association between FQR 
E.coli and ESBL production has been previously reported. A Turkish study has reported 
that 5.1% of ciprofloxacin resistant E.coli produced ESBL while none of the susceptible 
strains were ESBL producers (66). This association was found to be more consistent in 
E.coli when compared to Klebsiella pneumoniae in which ESBL production was found 
almost in equal proportions among FQ resistant and susceptible strains [61]. Earlier, 
Paterson et al have also reported a similar association [60]. Although the authors have 
suggested that mutations in the mar locus might be responsible for ESBL production and 
multiple antibiotic resistance [61, 95]  it is unlikely since according to our data we found 
equal proportions of ESBL producers among efflux positive and efflux negative strains. It 
is more likely that bacteria that are able to produce ESBL have additional survival 
advantages in the environment created by excessive fluoroquinolone use.  
This study identified ESBL in only 217 of the 219 cefotaxime resistant E.coli. 
Two strains did not have ESBL and neither tazobactam nor clavulanic acid improved the 
susceptibility to ßlactams. These two isolates were positive for efflux by the organic 
solvent tolerance test. Therefore it is possible that in a small number of isolates efflux 
alone is responsible for resistance to third generation cephalosporins. The therapeutic 
implication of this is that these infections may not respond to ß-lactam and ß-lactamase 
    
inhibitor combinations and may require therapy with antibiotics belonging to other groups 
like imipenem.  
It is well known that plasmids encoding ESBL can also carry genes coding for 
resistance to aminoglycosides and cotrimoxazole [60]. We found that 114 cefotaxime 
resistant strains were also resistant to aminoglycosides and cotrimoxazole in addition to 
fluoroquinolones.  
On comparing FQR from community acquired and hospital acquired infections 
there was no difference in the prevalence of high-level resistance to nalidixic acid and 
also in efflux-mediated resistance between the two groups. Although the overall 
prevalence of FQR is significantly different in these two populations, the proportion of 
different mechanisms of resistance appears to be similar in both groups. Therefore it is 
possible that FQR arising in the hospital is being transported to the community and 
propagated there.  
In the study of the epidemiology of E.coli, phenotypic characterization methods 
like antibiogram, serotyping and biotyping alone are not sufficient for coming to a 
conclusion regarding strain diversity or similarity [96]. Genotyping methods are required 
for subtle discrimination of various subgroups with in a bacterial population. Molecular 
epidemiology is essential for the understanding of the origin and spread of infective 
agents.  
FQR E.coli are known to have high mutational rates and therefore require a 
sensitive technique to study the clonal relatedness. In this study we adopted the RAPD 
typing method, which is sensitive enough to detect even a single point mutation anywhere 
in the genome. It is a rapid method and easy to perform. It has high discriminatory 
capacity and can detect subtle intraspecies variations [73, 84]. 
    
We found that there were great genetic variations among the FQR E.coli. 
Performing the RAPD typing with two primers, there were only two or three isolates, 
which were identical with each other. In the fluoroquinolone susceptible population 
nearly one third of the isolates belonged to a single group implying a common origin 
from where they mutate and diversify. The commensal E.coli also showed a large, related 
group of isolates suggesting a common ancestry. However there were differences between 
the individual isolates. Hospital acquired strains showed 2 clusters with 3 and 2 isolates 
each. These types of clusters were not seen in the community-acquired infecting group. 
Other than the two clusters that were identified, the other isolates were unrelated. This 
shows a multiclonal origin of drug resistant E.coli in the hospital environment. The 
clustering indicates the presence of cross infection in the hospital. 
The fluoroquinolone susceptible and resistant E.coli belonged to two different 
groups and were genetically unrelated. This type of grouping was not found within the 
FQR E.coli. 
A comparison of commensal and infecting strains showed that they were different 
genetically. This high degree of variability probably reflects the high mutation rates and 
therefore the random changes in the nucleotide that occurs at a high rate in these E.coli. 
These changes cannot be identified by any existing biotyping method. In this group there 
were several isolates with similar antibiogram but all of them were different by genetic 
typing. Therefore antibiogram alone is not useful method for identifying genetic 
relatedness especially in populations where multidrug resistance is common. RAPD 
proved to have high discriminatory power and identified many different types. 
 
 
 
    
  
 
         CONCLUSION
    
        The study was done to determine the mechanisms of fluoroquinolone resistance 
(FQR) among the E.coli causing urinary tract infections (UTI), its association with other 
antimicrobial resistance and genetic relatedness among them. The summary of the 
findings are as follows, 
1) Antimicrobial resistance was significantly more among  FQR E.coli when compared to 
fluoroquinolone susceptible E.coli. 
2) A significantly high number of FQR E.coli produced ESBL when compared to 
fluoroquinolone susceptible isolates.  
3) Multidrug resistance i.e. resistance to three or more groups of antimicrobials was 
significantly high among FQR E.coli. This might limit the choice of therapy and lead to 
therapeutic failures in the management of important infections. Further studies are 
required to understand why FQR, which is chromosomally mediated is significantly 
associated with plasmid mediated resistance like ESBL production. 
4) All the FQR E.coli had the phenotypic evidence of mutations in the genes encoding for 
the target enzymes like gyrA. Similar evidence was also found among 90% of 
fluoroquinolone susceptible E.coli, which were resistant to nalidixic acid. Limiting the 
use of fluoroquinolones in the treatment of infections caused by nalidixic resistant E.coli 
is necessary to prevent further evolution of resistant strains. 
5) In addition to target alterations 40% of FQR E.coli had up-regulated efflux pumps 
contributing to resistance.  
6) A significant number of the efflux positive isolates were multidrug resistant compared 
to efflux negative isolates. However 71% of efflux negative strains also exhibited MDR 
suggesting that factors other than efflux play a role in MDR. 
7) Up regulated efflux was significantly associated with nitrofurantoin resistance and also 
with cephalosporin resistance when compared to efflux negative FQR E.coli. 
    
8) Organic solvent tolerance test is simple and an easy test to perform even in small 
laboratories. 
9) Ninety nine percent of cefotaxime resistant FQR E.coli were ESBL producers. The 
remaining 1% were positive for efflux only. 
10) Although the prevalence of FQR is more among the hospital acquired E.coli when 
compared to the community acquired E.coli, the mechanisms of resistance were similar in 
both the groups. 
11) Genotyping by RAPD revealed that FQR E.coli belonged to many different clones. 
There were 115 RAPD types among the 120 isolates.  Genetic similarity was not common 
among the isolates tested. Limited clustering among the hospital acquired strains was 
seen, indicating the presence of cross infection. 
12) Grouping suggestive of a common origin was observed among the fluoroquinolone 
susceptible E.coli and also among FQR commensal E.coli. 
13) There was no evidence of genetic relatedness between fluoroquinolone susceptible 
and FQR E.coli. These two formed two separate groups in the NJTREE. 
14) RAPD is a sensitive technique with a high discriminatory power for determining 
genetic relatedness.
    
      
 
            APPENDIX 
    
 
Appendix I: 
Preparation of Luria agar with magnesium sulphate and glucose (LBMg agar): 
                              Ingredients: 
                                                 Bacto tryptone              1.0gm 
                                                 Bacto yeast extract        0.5gms       
                                                 Sodium chloride           1.5gms 
                                                 Magnesium sulphate     0.25gms 
                                                 Glucose                         0.001gms 
                                                  Agar                             1.5gms 
                                                  Distilled water             100ml 
The ingredients were mixed in water by heating. The pH was adjusted to 7.0 ± 0.2. 
Sterilized by autoclaving for 10 minutes at 121◦C.About 20 ml was poured into each of 
the glass petri dishes. 
Appendix II: 
Preparation of antibiotic solution: 
Concentration of the pure substance of nalidixic acid was 1mg =1000µgms. 
To obtain a final concentration of 2560µg /ml of nalidixic acid - 20mgs of nalidixic acid 
was diluted in 7.5 ml of distilled water and 0.3 ml of 1M NaOH was added 
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